Paul Quinlan - Cymabay Therapeu General Counsel, Corporate Secretary
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
Executive
Mr. Paul T. Quinlan is General Counsel, Corporationrationrate Secretary of the Company. Previously, he has served as our General Counsel and Corporationrationrate Secretary since December 2017. Previously, he served as General Counsel and Secretary at TerraVia Holdings, Inc., a biotechnology company, from 2010 to January 2018, where he was responsible for the general supervision of the companys legal affairs. From 2005 to 2010, Mr. Quinlan was General Counsel and Secretary at Metabolex, Inc., and from 2000 to 2005, Mr. Quinlan held various positions in the legal department at Maxygen, Inc., or Maxygen, most recently that of Chief Corporationrationrate Securities Counsel. Prior to joining Maxygen, Mr. Quinlan was an associate at Cooley LLP and Cravath, Swaine Moore LLP. Mr. Quinlan obtained a law degree from Columbia University Law School and a M.Sc. in Medical Biophysics from the University of Toronto. since 2017.
| Age | 61 |
| Tenure | 8 years |
| Phone | 510 293 8800 |
| Web | https://www.cymabay.com |
Paul Quinlan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Quinlan against Cymabay Therapeu stock is an integral part of due diligence when investing in Cymabay Therapeu. Paul Quinlan insider activity provides valuable insight into whether Cymabay Therapeu is net buyers or sellers over its current business cycle. Note, Cymabay Therapeu insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cymabay Therapeu'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Quinlan over six months ago Disposition of 41824 shares by Paul Quinlan of Cymabay Therapeu at 7.89 subject to Rule 16b-3 |
Cymabay Therapeu Management Efficiency
The company has return on total asset (ROA) of (0.2205) % which means that it has lost $0.2205 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6417) %, meaning that it created substantial loss on money invested by shareholders. Cymabay Therapeu's management efficiency ratios could be used to measure how well Cymabay Therapeu manages its routine affairs as well as how well it operates its assets and liabilities.Cymabay Therapeu currently holds 114.49 M in liabilities with Debt to Equity (D/E) ratio of 1.45, which is about average as compared to similar companies. Cymabay Therapeu has a current ratio of 11.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cymabay Therapeu's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Melita Jung | Terns Pharmaceuticals | 48 | |
| Paul Shin | 89bio Inc | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Catriona Yale | Akero Therapeutics | 53 | |
| Bob Gatmaitan | Structure Therapeutics American | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Yun Bai | 89bio Inc | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| David JD | Akero Therapeutics | N/A | |
| Carsten Boess | Kiniksa Pharmaceuticals | 58 | |
| Yingli Ma | Structure Therapeutics American | 51 | |
| Amanda Kurihara | 89bio Inc | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Caryn Peterson | Gossamer Bio | 66 | |
| Shiva CPA | 89bio Inc | 59 | |
| Colin Rowlings | Gossamer Bio | 60 | |
| JD Esq | Phathom Pharmaceuticals | N/A | |
| Thorsten Kirschberg | Biomea Fusion | 55 | |
| Carsten MBA | Kiniksa Pharmaceuticals | 59 | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 |
Cymabay Therapeu Leadership Team
Elected by the shareholders, the Cymabay Therapeu's board of directors comprises two types of representatives: Cymabay Therapeu inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cymabay. The board's role is to monitor Cymabay Therapeu's management team and ensure that shareholders' interests are well served. Cymabay Therapeu's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cymabay Therapeu's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Chief Officer | ||
| Paul Quinlan, General Counsel, Corporate Secretary | ||
| Patrick OMara, Senior Development | ||
| Robert Martin, Senior Development | ||
| Sujal Shah, CFO and Secretary | ||
| Klara DickinsonEason, Chief Officer | ||
| MBA MD, Chief Officer | ||
| Ken Boehm, Senior Resources | ||
| Harish CFA, Chief Officer | ||
| Ben Kozub, Head Commercial | ||
| Charles McWherter, Chief Scientific Officer and Sr. VP | ||
| Becki Filice, Senior Leadership | ||
| Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer |
Cymabay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cymabay Therapeu a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (745.58) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 99.49 % | |||
| Number Of Shares Shorted | 5.85 M | |||
| Price To Earning | (8.62) X | |||
| Price To Book | 12.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |